Pharmagen, Inc. (PHRX) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Pharmagen, Inc. (PHRX) Healthcare & Pipeline Overview

Pharmagen, Inc. specializes in the distribution of specialty drugs, blood plasma derivatives, and hard-to-find pharmaceuticals to U.S. healthcare facilities. The company also manufactures health supplements like Clotamin and offers drug formulation services, positioning itself as a diversified provider within the medical distribution sector, serving critical patient needs with a focused product portfolio.

What Is the Investment Thesis for PHRX?

Pharmagen, Inc. operates within the essential medical distribution sector, focusing on high-demand specialty drugs, blood plasma derivatives, and hard-to-find pharmaceuticals for U.S. healthcare facilities. A key value driver is its established distribution network, which provides access to critical medications for hospitals and acute care centers. The company's diversified product portfolio, including niche health supplements like Clotamin for Warfarin patients, offers potential for market penetration in specialized consumer health segments. Growth catalysts include the expanding market for specialty drugs and plasma derivatives, driven by advancements in medical treatments and an aging population. Additionally, its drug formulation capabilities could unlock future proprietary product development or contract manufacturing opportunities. However, the company's significant negative profit margin of -134.2% and its classification on the OTC Other tier present ongoing operational and financial challenges that require careful consideration.

Based on FMP financials and quantitative analysis

PHRX Key Highlights

Pharmagen, Inc. operates with a negative profit margin of -134.2%, indicating substantial unprofitability relative to its revenue.

• The company maintains a gross margin of 63.3%, suggesting strong profitability on its core product sales before operating expenses.
• With a market capitalization of $0.00 billion, Pharmagen, Inc. is classified as a micro-cap entity, reflecting its small size in the public markets.
• The company's Beta of 0.32 indicates significantly lower volatility compared to the broader market, suggesting a relatively stable stock price movement.
• Pharmagen, Inc. currently employs 24 individuals, highlighting a lean operational structure for its distribution and manufacturing activities.

Who Are PHRX's Competitors?

PHRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PHRX's Key Strengths?

Specialization in high-demand specialty drugs and hard-to-find pharmaceuticals.

• Diverse product portfolio including plasma derivatives, vaccines, and health supplements.
• Established distribution network serving various U.S. healthcare facilities.
• Proprietary health supplement (Clotamin) addressing a specific patient need.
• Internal capabilities in drug formulation, offering potential for product development.

What Are PHRX's Weaknesses?

Significant negative profit margin of -134.2%, indicating substantial unprofitability.

• Small employee base of 24, potentially limiting scalability and operational capacity.
• Trades on the OTC market, which can entail lower liquidity and less stringent reporting requirements.
• Unknown disclosure status on the OTC market, posing transparency challenges for investors.
• Market capitalization of $0.00 billion suggests a very small operational scale and limited access to capital markets.

What Could Drive PHRX Stock Higher?

PHRX catalyst: Expansion of distribution agreements for specialty drugs to new healthcare networks, potentially increasing market reach and revenue streams.

• Growth in demand for blood plasma derivatives, driven by increasing diagnoses of conditions like hemophilia and immune deficiencies, directly benefiting Pharmagen's core distribution business.
• Successful introduction of new drug formulations or proprietary products, leveraging the company's formulation expertise to create higher-margin offerings.
• Increased market penetration and consumer adoption of the Clotamin health supplement, expanding its presence in the specialized dietary supplement market.
• Strategic partnerships or collaborations with pharmaceutical manufacturers to enhance product sourcing or expand distribution capabilities.

What Are the Key Risks for PHRX?

Significant negative profit margin of -134.2% indicates persistent operational losses, posing a threat to long-term financial sustainability.

• Intense competition from larger, well-capitalized pharmaceutical distributors could erode market share and pricing power for Pharmagen's offerings.
• Regulatory risks associated with pharmaceutical distribution and drug formulation, including compliance costs and potential for product recalls or changes in approval processes.
• Supply chain disruptions for specialty drugs and blood plasma derivatives, which are often complex and sensitive, could impact product availability and customer satisfaction.
• Challenges related to trading on the 'OTC Other' market, including limited liquidity, potential for price manipulation, and difficulty in attracting institutional investment due to unknown disclosure status.

What Are the Growth Opportunities for PHRX?

• **Specialty Drug Market Expansion**: The global specialty drug market is experiencing robust growth, driven by advancements in biotechnology, increasing prevalence of complex diseases, and the development of targeted therapies. Pharmagen, with its established distribution network for specialty drugs, is strategically positioned to capitalize on this expansion. This includes sourcing and distributing advanced treatments for conditions like cancer, autoimmune disorders, and rare diseases, which often require specialized handling, cold chain logistics, and expedited delivery. The focus on 'hard-to-find pharmaceuticals' further solidifies its niche, appealing to facilities that struggle to acquire such critical medications, thereby offering a clear avenue for revenue growth in a high-value market segment.
• **Blood Plasma Derivatives Demand**: The market for blood plasma derivatives, essential for treating serious medical conditions such as hemophilia, primary immunodeficiencies, and neurological disorders, is projected to continue its upward trajectory. Pharmagen's role in distributing these life-saving biological products positions it directly within a high-demand, medically essential segment. As new therapeutic indications for plasma-derived therapies emerge and global healthcare access improves, the demand for these products is expected to rise steadily. Pharmagen's capability to reliably supply these critical biologicals to acute care facilities and hospitals represents a stable and growing revenue stream, supported by ongoing medical advancements and persistent patient needs.
• **Clotamin Health Supplement Penetration**: The Clotamin over-the-counter multivitamin, specifically formulated for patients on Warfarin, addresses a unique and significant market need within the specialized dietary supplement sector. With millions of individuals globally prescribed Warfarin for anticoagulation, the demand for tailored nutritional support to manage potential interactions and side effects is substantial. Expanding the distribution and marketing of Clotamin beyond its current reach, potentially through pharmacy channels or direct-to-consumer strategies, could unlock significant growth. This product offers a diversification of Pharmagen's revenue streams beyond institutional sales, tapping into the growing market for specialized health supplements, which is projected to expand steadily over the next decade.
• **Traditional Pharmaceutical Distribution Enhancement**: While specializing in niche products, Pharmagen also maintains a foundational business in distributing traditional pharmaceuticals, including antibiotics and vaccines. This segment provides a consistent revenue stream and allows the company to leverage its existing distribution infrastructure efficiently. As healthcare facilities increasingly seek consolidated suppliers, Pharmagen's ability to offer a comprehensive range of products, from highly specialized to commonly used, can enhance its value proposition. Expanding its portfolio of high-demand traditional injectables and oral medications can help secure larger contracts and increase market share within the broader pharmaceutical distribution landscape, ensuring consistent operational volume and customer loyalty.
• **Drug Formulation Services Expansion**: Pharmagen's stated specialization in drug formulation presents a significant opportunity to move up the value chain beyond solely distribution. This capability allows the company to potentially develop proprietary products, create custom formulations for specific patient populations, or offer contract manufacturing services to other pharmaceutical entities. By leveraging its expertise in creating specific drug formulations, Pharmagen could target niche markets with unmet needs or develop improved versions of existing medications. This strategic pivot or expansion could lead to higher-margin revenue streams, the development of valuable intellectual property, and a stronger competitive position, potentially attracting partnerships or licensing agreements in the long term.

What Are PHRX's Competitive Advantages?

• **Specialization in Niche Products**: Focus on hard-to-find pharmaceuticals and specific specialty drugs creates a barrier to entry for general distributors.
• **Established Distribution Network**: A proven logistics and supply chain infrastructure for delivering sensitive and critical medications to healthcare facilities.
• **Proprietary Health Supplement**: Ownership of Clotamin, a specialized OTC product for a specific patient demographic, offers a unique market position.
• **Drug Formulation Capabilities**: Internal expertise in drug formulation provides a potential competitive edge for developing unique products or offering specialized services.

What Does PHRX Do?

Pharmagen, Inc., headquartered in Silver Spring, Maryland, operates as a specialized distributor within the United States healthcare sector. The company's origins trace back to its former identity as Sunpeaks Ventures, Inc., before undergoing a strategic rebranding and changing its name to Pharmagen, Inc. in January 2013. This evolution marked a focused commitment to the medical distribution industry, catering to a diverse clientele that includes hospitals, acute care facilities, surgery centers, and other healthcare practitioners across the nation. At its core, Pharmagen sources and distributes a comprehensive array of critical medical products. This portfolio encompasses specialty drugs, which often require specific handling and expertise, alongside essential blood plasma derivatives vital for treating a range of serious medical conditions such as cancer, hemophilia, rheumatoid arthritis, multiple sclerosis, blood disorders, hepatitis, and HIV. The company further extends its offerings to include specialty products targeting respiratory, oncology, cardiovascular, and hormonal syndromes, addressing complex patient needs with targeted therapeutic solutions. Beyond these specialized areas, Pharmagen maintains a robust distribution channel for traditional pharmaceuticals, including antibiotics, vaccines, and other oral and injectable medications, serving as a comprehensive supplier to its customers. In a strategic diversification move, Pharmagen also engages in the manufacturing and distribution of health supplements. A notable product in this segment is Clotamin, a specialized over-the-counter multivitamin dietary supplement specifically formulated for patients undergoing Warfarin therapy. This product highlights the company's ability to identify and cater to niche market demands within the broader health and wellness landscape. Furthermore, Pharmagen distinguishes itself through its specialization in the formulation of drugs, indicating an internal capability to develop and customize pharmaceutical products, which complements its primary distribution activities and enhances its value proposition within the healthcare supply chain.

What Products and Services Does PHRX Offer?

• Distributes specialty drugs to hospitals and acute care facilities in the United States.
• Sources and distributes blood plasma derivatives for serious medical conditions like cancer, hemophilia, and HIV.
• Provides specialty products for respiratory, oncology, cardiovascular, and hormonal syndromes.
• Manufactures and distributes health supplements, including Clotamin, an OTC multivitamin for Warfarin patients.
• Sells traditional pharmaceuticals such as antibiotics, vaccines, and other oral/injectable medications.
• Specializes in the formulation of drugs, indicating internal development capabilities.
• Serves surgery centers and other healthcare practitioners with its diverse product portfolio.

How Does PHRX Make Money?

• **Distribution Services**: Generates revenue by sourcing and delivering a wide range of pharmaceuticals, including specialty drugs, plasma derivatives, and traditional medications, to healthcare providers.
• **Proprietary Product Sales**: Earns revenue from the manufacturing and sale of its own health supplements, such as Clotamin, directly to consumers or through retail channels.
• **Formulation Expertise**: Potentially derives revenue from its drug formulation capabilities, which could involve contract development or the creation of new proprietary products.
• **Supply Chain Management**: Leverages its logistics and supply chain expertise to ensure efficient and reliable delivery of critical medications, charging for these value-added services.

What Industry Does PHRX Operate In?

Pharmagen, Inc. operates within the highly regulated and essential Medical - Distribution industry in the United States, a sector characterized by complex supply chains and stringent quality control requirements. This industry is critical for ensuring the timely and efficient delivery of pharmaceuticals and medical supplies to healthcare providers. Pharmagen carves out a niche by specializing in specialty drugs, blood plasma derivatives, and hard-to-find pharmaceuticals, differentiating itself from larger, more generalized distributors. The broader medical distribution market is influenced by trends such as increasing demand for personalized medicine, growth in chronic disease management, and the ongoing need for efficient logistics. While facing competition from established players, Pharmagen's focus on specialized and critical products allows it to serve specific segments of the healthcare market. Its ability to source and distribute these unique items positions it as a vital link for facilities requiring non-standard or difficult-to-procure medications.

Who Are PHRX's Key Customers?

• Hospitals across the United States requiring specialty and traditional pharmaceuticals.
• Acute care facilities seeking critical blood plasma derivatives and anti-infectives.
• Surgery centers in need of a reliable supply of various medications.
• Other healthcare practitioners, including clinics and specialized treatment centers.
• Patients on Warfarin therapy, who are target consumers for its Clotamin health supplement.

Company Profile

Pharmagen, Inc. operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Silver Spring, US. The company is led by CEO Mackie A. Barch. PHRX has traded publicly since 2012.

Pharmagen, Inc. (PHRX) Valuation Context

Relative to its peer group, PHRX's quantitative score of 55/100 is roughly in line with the peer average of 47/100.

Return on equity for Pharmagen, Inc. stands at 85.1%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -14.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.11 means current liabilities exceed short-term assets, a liquidity point worth watching.

PHRX Financials

PHRX Latest News

No recent news available for PHRX.

PHRX Analyst Consensus

PHRX MoonshotScore

PHRX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources